Related references
Note: Only part of the references are listed.Dual Nicotinamide Phosphoribosyltransferase (NAMPT) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors for the Treatment of Drug-Resistant Nonsmall-Cell Lung Cancer
Kaizhen Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2023)
Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
Kostas A. A. Papavassiliou et al.
CANCERS (2023)
Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors
Ji Zhou et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)
STAT proteins in cancer: orchestration of metabolism
Yi-Jia Li et al.
NATURE REVIEWS CANCER (2023)
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy
Kai Tang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Inhibition of STAT3 reverses Taxol-resistance in ovarian cancer by down-regulating G6PD expression in vitro
Hao Sheng et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2022)
Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma
Lakshmi R. Bollu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy
Ya Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Hybridization Approach to Identify Salicylanilides as Inhibitors of Tubulin Polymerization and Signal Transducers and Activators of Transcription 3 (STAT3)
Marta Gargantilla et al.
PHARMACEUTICALS (2022)
HDAC/JAK dual target inhibitors of cancer-related targets: The success of nonclearable linked pharmacophore mode
Liyun Zhao et al.
BIOORGANIC CHEMISTRY (2022)
Paradigm shift of classical HDAC inhibitors to hybrid HDAC inhibitors in therapeutic interventions
Gargi Nikhil Vaidya et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors
Amr K. A. Bass et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy
Manlio Tolomeo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy
Mengjiao Zhou et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Recent advances of quinones as a privileged structure in drug discovery
Li Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer
Nagendra Awasthi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
The ups, downs and new trends of IDO1 inhibitors
Shulun Chen et al.
BIOORGANIC CHEMISTRY (2021)
Melatonin derivatives combat with inflammation-related cancer by targeting the Main Culprit STAT3
Shumeng Ma et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Polyphenolic molecules targeting STAT3 pathway for the treatment of cancer
Md Abdul Aziz et al.
LIFE SCIENCES (2021)
LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer
Mengxing Li et al.
COMMUNICATIONS BIOLOGY (2021)
Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer
Yuhao Ren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation
Jinyun Dong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
The Evolution of Cancer Immunotherapy
Meshaal Khan et al.
VACCINES (2021)
Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
Loredana Cappellacci et al.
CURRENT MEDICINAL CHEMISTRY (2020)
Melatonin modulates airway smooth muscle cell phenotype by targeting the STAT3/Akt/GSK-3β pathway in experimental asthma
Qijun Yu et al.
CELL AND TISSUE RESEARCH (2020)
Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3
Rizhen Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Revisiting the development of small molecular inhibitors that directly target the signal transducer and activator of transcription 3 (STAT3) domains
Po-Chang Shih
LIFE SCIENCES (2020)
Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1
Mingxing Hu et al.
ACTA PHARMACEUTICA SINICA B (2020)
Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer
Baosheng Chen et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
Tingting Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Identification of Histone deacetylase (HDAC)-Associated Proteins with DNA-Programmed Affinity Labeling
Jianfu Zhang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer
Mingming Wei et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Targeting STAT3 in cancer and autoimmune diseases
Tohid Gharibi et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Terence C. S. Ho et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities
Daniel A. Rodrigues et al.
MEDICINAL RESEARCH REVIEWS (2020)
Targeting STAT3 in Cancer Immunotherapy
Sailan Zou et al.
MOLECULAR CANCER (2020)
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment
Xiaopeng Peng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective
Xi Feng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer
Yuki Kiyozumi et al.
ANNALS OF SURGERY (2019)
Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds
Ewgenij Proschak et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains
Fatima Naaz et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Michael Platten et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Harnessing Polypharmacology with Medicinal Chemistry
Maria Laura Bolognesi
ACS MEDICINAL CHEMISTRY LETTERS (2019)
The emergence of melatonin in oncology: Focus on colorectal cancer
Emilio Gil-Martin et al.
MEDICINAL RESEARCH REVIEWS (2019)
BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo
Shilei Liu et al.
CANCER SCIENCE (2019)
A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis
Zhen Xiang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Targeting STAT3 inhibition to reverse cisplatin resistance
Chao-Yue Sung et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Novel activators and small-molecule inhibitors of STAT3 in cancer
Lehe Yang et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2019)
Multi-Targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship
Harbinder Singh et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2019)
Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials
Amaia Eleonora Maennling et al.
CANCERS (2019)
Highlighted STAT3 as a potential drug target for cancer therapy
Haeri Lee et al.
BMB REPORTS (2019)
Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications
Zixiang Ye et al.
JOURNAL OF CANCER (2019)
N-Arylsulfonylsubstituted-1H indole derivatives as small molecule dual inhibitors of signal transducer and activator of transcription 3 (STAT3) and tubulin
Qiang Zhou et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance
Tianyi Wang et al.
CELL METABOLISM (2018)
The side effects of platinum-based chemotherapy drugs: a review for chemists
Rabbab Oun et al.
DALTON TRANSACTIONS (2018)
Pterostilbene Suppresses Ovarian Cancer Growth via Induction of Apoptosis and Blockade of Cell Cycle Progression Involving Inhibition of the STAT3 Pathway
Wei Wen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Structural Biology of STAT3 and Its Implications for Anticancer Therapies Development
Jacopo Sgrignani et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies
Loukik Arora et al.
CANCERS (2018)
Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1
Elisa Albini et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2017)
An in vivo active 1,2,5-oxadiazole Pt(II) complex: A promising anticancer agent endowed with STAT3 inhibitory properties
Federica Porta et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Designing multi-targeted agents: An emerging anticancer drug discovery paradigm
Rong-geng Fu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
B1, a novel HDAC inhibitor, induces apoptosis through the regulation of STAT3 and NF-κB
Meng-Hsuan Cheng et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2017)
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
Yuankai Shi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat
Chiara Zagni et al.
MEDICINAL RESEARCH REVIEWS (2017)
STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics
Ahmad A. Zulkifli et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2017)
Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1
Ariel Lewis-Ballester et al.
NATURE COMMUNICATIONS (2017)
An anti-prostate cancer benzofuran-conjugated iridium(III) complex as a dual inhibitor of STAT3 and NF-κB
Tian-Shu Kang et al.
CANCER LETTERS (2017)
Strategies and Approaches of Targeting STAT3 for Cancer Treatment
Stefanie L. Furtek et al.
ACS CHEMICAL BIOLOGY (2016)
Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer
Hanlin Zeng et al.
CANCER CELL (2016)
EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB
Gianluca Civenni et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Targeting transcription factor STAT3 for cancer prevention and therapy
Edna Zhi Pei Chai et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism
Chengguang Zhao et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Hypothalamic leptin action is mediated by histone deacetylase 5
Dhiraj G. Kabra et al.
NATURE COMMUNICATIONS (2016)
Biological and medicinal significance of benzofuran
Reshma J. Nevagi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
A STAT inhibitor patent review: progress since 2011
Ping-Shan Lai et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2015)
N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling
Mei-Jung Lai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer
Yu Fujita et al.
MOLECULAR THERAPY (2015)
STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell
Lin-Lin Bu et al.
ONCOTARGET (2015)
Multi-target pharmacology: possibilities and limitations of the skeleton key approach from a medicinal chemist perspective
Alan Talevi
FRONTIERS IN PHARMACOLOGY (2015)
Emerging cytokine networks in colorectal cancer
Nathan R. West et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Recent developments in tubulin polymerization inhibitors: An overview
Ramandeep Kaur et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
New and emerging HDAC inhibitors for cancer treatment
Alison C. West et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Identification of a natural product-like STAT3 dimerization inhibitor by structure-based virtual screening
L-J Liu et al.
CELL DEATH & DISEASE (2014)
Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR
Ulrike M. Litzenburger et al.
ONCOTARGET (2014)
Chronic Inflammation and Cytokines in the Tumor Microenvironment
Glauben Landskron et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2014)
gp130: a promising drug target for cancer therapy
Shili Xu et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials
Tianzhu Qiu et al.
FUTURE ONCOLOGY (2013)
LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/stat3/akt pathway
Xuan Song et al.
MOLECULAR CANCER (2013)
Emerging molecular targets in melanoma invasion and metastasis
Jose L. Orgaz et al.
PIGMENT CELL & MELANOMA RESEARCH (2013)
Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
Muhammad Furqan et al.
BIOMARKER RESEARCH (2013)
A Metal-Based Inhibitor of Tumor Necrosis Factor-α
Chung-Hang Leung et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells
Shuling Huang et al.
CANCER LETTERS (2012)
Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy
M. Gupta et al.
LEUKEMIA (2012)
Automated design of ligands to polypharmacological profiles
Jeremy Besnard et al.
NATURE (2012)
Biological and computational evaluation of an oxadiazole derivative (MD77) as a new lead for direct STAT3 inhibitors
Daniela Masciocchi et al.
MEDCHEMCOMM (2012)
Tryptophan metabolism, from nutrition to potential therapeutic applications
Nathalie Le Floc'h et al.
AMINO ACIDS (2011)
Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors
Arun K. Mankan et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes
Xiaolei Zhang et al.
BIOCHEMICAL PHARMACOLOGY (2010)
AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit
Tzu-Yin Lin et al.
BLOOD (2010)
Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
Sergei I. Grivennikov et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2010)
Nonhistone protein acetylation as cancer therapy targets
Brahma N. Singh et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
Microtubule-Targeted Chemotherapeutic Agents Inhibit Signal Transducer and Activator of Transcription 3 (STAT3) Signaling
Sarah R. Walker et al.
MOLECULAR PHARMACOLOGY (2010)
Microtubule-binding agents: a dynamic field of cancer therapeutics
Charles Dumontet et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Synthesis, modeling, and crystallographic study of 3,4-disubstituted-1,2,5-oxadiazoles and evaluation of their ability to decrease STAT3 activity
Dae-Seop Shin et al.
MEDCHEMCOMM (2010)
Identification of a New Series of STAT3 Inhibitors by Virtual Screening
Kenji Matsuno et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Microtubules and resistance to tubulin-binding agents
Maria Kavallaris
NATURE REVIEWS CANCER (2010)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
Development of a STAT3 reporter prostate cancer cell line for high throughput screening of STAT3 activators and inhibitors
My N. Chau et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Histone deacetylase inhibitors: From bench to clinic
Marielle Paris et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis
Ciriana Orabona et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Michal Marzec et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The resurgence of platinum-based cancer chemotherapy
Lloyd Kelland
NATURE REVIEWS CANCER (2007)
Direct cellular responses to platinum-induced DNA damage
Yongwon Jung et al.
CHEMICAL REVIEWS (2007)
Molecular mechanisms of resistance and toxicity associated with platinating agents
Cara A. Rabik et al.
CANCER TREATMENT REVIEWS (2007)
Targeting Microtubules to inhibit angiogenesis and disrupt tumour vasculature: Implications for cancer treatment
Eddy Pasquier et al.
CURRENT CANCER DRUG TARGETS (2007)
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Hua Yu et al.
NATURE REVIEWS IMMUNOLOGY (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
M Kortylewski et al.
NATURE MEDICINE (2005)
Designed multiple ligands. An emerging drug discovery paradigm
R Morphy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Immunosuppressive networks in the tumour environment and their therapeutic relevance
WP Zou
NATURE REVIEWS CANCER (2005)
Microtubules as a target for anticancer drugs
MA Jordan et al.
NATURE REVIEWS CANCER (2004)
The stats of cancer - New molecular targets come of age
H Yu et al.
NATURE REVIEWS CANCER (2004)
Histone deacetylases (HDACs): characterization of the classical HDAC family
AJM De Ruijter et al.
BIOCHEMICAL JOURNAL (2003)
Transcription factors as targets for cancer therapy
JE Darnell
NATURE REVIEWS CANCER (2002)
Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors
T Hirano et al.
ONCOGENE (2000)
Share Paper
